Tango Therapeutics Achieves 92% Response Rate in Hard-to-Treat Pancreatic Cancer
Tango drug combo shows 92% response in advanced pancreatic cancer, with strong early results and good safety in trials.
Tango drug combo shows 92% response in advanced pancreatic cancer, with strong early results and good safety in trials.
Mizuho starts coverage on Tango Therapeutics with an Outperform rating and $19 price target, highlighting strong potential for lead drug vopimetostat in tough cancers like pancreatic and lung.
Stifel initiates coverage of Tango Therapeutics with a Buy rating and $15 target, citing strong potential for its PRMT5 inhibitor vopimetostat and forecasting $1.2B in peak global revenue by 2035.